Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Cardiovascular disease remains one of the leading causes of illness and death worldwide, placing significant pressure on healthcare systems and highlighting the importance of early diagnosis and timely intervention. As digital health technologies continue to evolve, wearable devices and artificial…
Behind every successful healthcare system is a supply chain that ensures medicines, medical devices and essential equipment reach the right place at the right time. While often operating behind the scenes, healthcare logistics has become one of the most important…
Attendees
Sponsors and Exhibitors
Contact us